Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05174169 · ClinicalTrials.gov registry record · Phase 2

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

A Phase 2 study of Stage III Colon Cancer, sponsored by NRG Oncology.

Recruiting
Registry status
Phase 2
Development phase
1,912
Enrollment target
20
Study locations

NCT05174169 is a Phase 2 study of Stage III Colon Cancer that is actively recruiting participants, run by NRG Oncology. The registered enrollment target is 1,912 participants, above the 498-participant average among 6 other Stage III Colon Cancer trials with a reported enrollment target (284% higher). The trial reports 20 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05174169, a Phase 2 study of Stage III Colon Cancer, is actively recruiting participants, sponsored by NRG Oncology.

RECRUITING
Registry status
Phase 2
Development phase
1,912 participants
Enrollment target
20
Study locations

Study Summary

This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.

Conditions Studied

Stage III Colon Cancer

Interventions

  • DEVICE Signatera test
  • DRUG mFOLFOX6 3-6 month
  • DRUG CAPOX 3 month
  • DRUG mFOLFIRINOX
  • DRUG mFOLFOX6 6 month

Study Locations (20)

California

  • Kaiser Permanente-Anaheim - Anaheim
  • Kaiser Permanente-Deer Valley Medical Center - Antioch
  • Mission Hope Medical Oncology - Arroyo Grande - Arroyo Grande
  • PCR Oncology - Arroyo Grande
  • Sutter Auburn Faith Hospital - Auburn
  • Sutter Cancer Centers Radiation Oncology Services-Auburn - Auburn
  • AIS Cancer Center at San Joaquin Community Hospital - Bakersfield

Arizona

  • Kingman Regional Medical Center - Kingman
  • Cancer Center at Saint Joseph's - Phoenix
  • Mayo Clinic Hospital in Arizona - Phoenix
  • Banner University Medical Center - Tucson - Tucson
  • University of Arizona Cancer Center-North Campus - Tucson

Alabama

  • University of Alabama at Birmingham Cancer Center - Birmingham
  • Thomas Hospital - Fairhope
  • Mobile Infirmary Medical Center - Mobile
  • University of South Alabama Mitchell Cancer Institute - Mobile

Arkansas

  • Mercy Hospital Fort Smith - Fort Smith
  • CHI Saint Vincent Cancer Center Hot Springs - Hot Springs
  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro - Jonesboro
  • University of Arkansas for Medical Sciences - Little Rock

Trial Details

FieldValue
Enrollment Target 1,912 participants
Start Date 2022-03-10
Est. Completion 2030-03-10
Phase Phase 2

Sponsor

NRG Oncology

64 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05174169

The ClinicalTrials.gov registry entry for NCT05174169 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 1,912 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 498-participant average among 6 other Stage III Colon Cancer trials with a reported enrollment target (284% higher). The listed sponsor is NRG Oncology, which has 64 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Stage III Colon Cancer appearing as the primary indexed condition, and to 5 interventions - of which Signatera test is the first listed.

NCT05174169 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Alabama.

Frequently Asked Questions

What is clinical trial NCT05174169 about?

NCT05174169 is a clinical study titled "Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease". This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.

What is the current status of trial NCT05174169?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 1,912 participants. The study started on 2022-03-10. Estimated completion is 2030-03-10.

What conditions does trial NCT05174169 study?

This clinical trial studies the following conditions: Stage III Colon Cancer.

What interventions are being tested in trial NCT05174169?

The interventions under investigation include: Signatera test (DEVICE), mFOLFOX6 3-6 month (DRUG), CAPOX 3 month (DRUG), mFOLFIRINOX (DRUG), mFOLFOX6 6 month (DRUG).

Who is sponsoring clinical trial NCT05174169?

This trial is sponsored by NRG Oncology, which has 64 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05174169 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Stage III Colon Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Stage III Colon Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.